NASDAQ:MBRX Moleculin Biotech (MBRX) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free MBRX Stock Alerts $4.44 +0.14 (+3.26%) (As of 10:54 AM ET) Add Compare Share Share Today's Range$4.29▼$4.4550-Day Range$4.28▼$10.3252-Week Range$4.28▼$15.75Volume3,616 shsAverage Volume30,046 shsMarket Capitalization$9.90 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Moleculin Biotech alerts: Email Address Moleculin Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside714.0% Upside$35.00 Price TargetShort InterestHealthy2.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($10.93) to ($8.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.15 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMoleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMoleculin Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.09% of the float of Moleculin Biotech has been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently increased by 2,042.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MBRX. Previous Next 2.4 News and Social Media Coverage News SentimentMoleculin Biotech has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Moleculin Biotech this week, compared to 1 article on an average week.Search Interest7 people have searched for MBRX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Moleculin Biotech is held by insiders.Percentage Held by InstitutionsOnly 15.52% of the stock of Moleculin Biotech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Moleculin Biotech are expected to grow in the coming year, from ($10.93) to ($8.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moleculin Biotech is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moleculin Biotech is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Moleculin Biotech Stock (NASDAQ:MBRX)Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.Read More MBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MBRX Stock News HeadlinesApril 21, 2024 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.comApril 18, 2024 | markets.businessinsider.comMoleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AMLApril 23, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 18, 2024 | prnewswire.comEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)April 14, 2024 | americanbankingnews.comRoth Mkm Reiterates Buy Rating for Moleculin Biotech (NASDAQ:MBRX)April 13, 2024 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.comApril 12, 2024 | investing.comMoleculin Biotech Inc (MBRX)April 10, 2024 | markets.businessinsider.comMoleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic EffectsApril 23, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 10, 2024 | prnewswire.comMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesMarch 28, 2024 | finance.yahoo.comMoleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 27, 2024 | finance.yahoo.comMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLMarch 27, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityMarch 26, 2024 | finance.yahoo.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call TranscriptMarch 25, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialMarch 25, 2024 | markets.businessinsider.comMoleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AMLMarch 25, 2024 | finance.yahoo.comMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialMarch 23, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports Full Year 2023 Financial ResultsMarch 22, 2024 | investorplace.comMBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023March 22, 2024 | finance.yahoo.comMoleculin Biotech Inc Reports Fiscal Year 2023 Financial ResultsMarch 22, 2024 | prnewswire.comMoleculin Reports Full Year 2023 Financial ResultsMarch 21, 2024 | investing.comMoleculin Biotech announces 1-for-15 reverse stock splitMarch 21, 2024 | benzinga.comA Preview Of Moleculin Biotech's EarningsMarch 20, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Announces Reverse Stock SplitMarch 20, 2024 | prnewswire.comMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and WebcastMarch 19, 2024 | finance.yahoo.comMoleculin Announces Reverse Stock SplitMarch 12, 2024 | finance.yahoo.comMoleculin to Present at the 36th Annual ROTH ConferenceSee More Headlines Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2023Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MBRX CUSIPN/A CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$45.00 Low Stock Price Target$20.00 Potential Upside/Downside+714.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($13.6432) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.91% Return on Assets-67.69% Debt Debt-to-Equity RatioN/A Current Ratio3.86 Quick Ratio3.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.70 per share Price / Book0.37Miscellaneous Outstanding Shares2,230,000Free Float2,078,000Market Cap$9.59 million OptionableNot Optionable Beta1.96 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Walter V. Klemp (Age 64)Founder, Chairman, President & CEO Comp: $894.54kMr. Jonathan P. Foster CPA (Age 60)Executive VP & CFO Comp: $611.17kDr. Donald H. Picker Ph.D. (Age 78)Chief Scientific Officer Comp: $486.44kDr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory BoardDr. Robert C. Shepard FACP (Age 72)M.D., Chief Medical Officer of Annamycin Dr. John Paul Waymack M.D. (Age 72)Sc.D., Senior Chief Medical Officer Dr. Sandra L. Silberman M.D. (Age 68)Ph.D., Chief Medical Officer of New Products Dr. Wolfram C. M. Dempke M.B.A.M.D., Ph.D., European Chief Medical OfficerMs. Jacqueline Northcut (Age 62)Consultant Comp: $51.11kMr. Louis Ploth Jr. (Age 70)Independent Advisor Comp: $118.49kMore ExecutivesKey CompetitorsAlterity TherapeuticsNASDAQ:ATHEAeterna ZentarisNASDAQ:AEZSGuardion Health SciencesNASDAQ:GHSIGalera TherapeuticsNASDAQ:GRTXBiofronteraNASDAQ:BFRIView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 3,207,417 shares on 2/13/2024Ownership: 9.600%Walter V KlempBought 12,560 shares on 12/26/2023Total: $129,996.00 ($10.35/share)Jonathan P FosterBought 1,932 shares on 12/26/2023Total: $19,996.20 ($10.35/share)Robert E GeorgeBought 966 shares on 12/26/2023Total: $9,998.10 ($10.35/share)View All Insider TransactionsView All Institutional Transactions MBRX Stock Analysis - Frequently Asked Questions Should I buy or sell Moleculin Biotech stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares. View MBRX analyst ratings or view top-rated stocks. What is Moleculin Biotech's stock price target for 2024? 3 analysts have issued 12-month price objectives for Moleculin Biotech's shares. Their MBRX share price targets range from $20.00 to $45.00. On average, they anticipate the company's share price to reach $35.00 in the next year. This suggests a possible upside of 714.0% from the stock's current price. View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts. How have MBRX shares performed in 2024? Moleculin Biotech's stock was trading at $12.8760 at the start of the year. Since then, MBRX stock has decreased by 66.6% and is now trading at $4.30. View the best growth stocks for 2024 here. Are investors shorting Moleculin Biotech? Moleculin Biotech saw a increase in short interest in March. As of March 31st, there was short interest totaling 45,000 shares, an increase of 2,042.9% from the March 15th total of 2,100 shares. Based on an average daily volume of 31,900 shares, the short-interest ratio is currently 1.4 days. Approximately 2.1% of the company's shares are short sold. View Moleculin Biotech's Short Interest. When is Moleculin Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MBRX earnings forecast. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) released its quarterly earnings data on Friday, August, 11th. The company reported ($3.00) EPS for the quarter, topping the consensus estimate of ($4.20) by $1.20. During the same quarter in the prior year, the business earned ($3.60) EPS. When did Moleculin Biotech's stock split? Shares of Moleculin Biotech reverse split before market open on Friday, March 22nd 2024. The 1-15 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL). How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MBRX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
